Skip to main content
Figure 5 | Breast Cancer Research

Figure 5

From: Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillanceby Enhancing Intratumoral Immune Checkpoint Activity

Figure 5

COX-2 knock down reduced tumor cell PD-L1 expression and orthotopic tumorgrowth. ErbB2-transformed mammary epithelial cells (NAF) were transducedwith non-targeted shRNA (NAF nt) or COX-2 targeted shRNA (NAF COX-2KD). (A) COX-2 mRNA levels measured by Q-PCR, after 24 hours of treatment with 5μg/ml LPS (n = 4). (B) Percent of tumor free mice aftermammary fat pad injection of NAF nt and NAF COX-2KD (n = 6). (C) Mean fluorescence of PD-L1 in NAF, measured by flow cytometry, after 48hours of treatment with 10 ng/ml IFNγ, with or without 250 nM PGE2 (n = 3 to 6). Data in column graphs are mean ± sem.P values are compared to NAF nt control, unless otherwiseindicated. *P < 0.05, **P < 0.005, ***P <0.0005. COX, cyclooxygenase; KO, knock out; shRNA, short hairpin RNA.

Back to article page